Ann Arbor, Michigan – Visiun announced today the addition of test utilization to the cloud-based version of its leading laboratory analytics system, Performance Insight™. Visiun’s test utilization ...

Does payer coverage of genomic testing drive utilization? That is the question The Personalized Medicine Coalition (“PMC”) asked and answered in its recent report “Understanding Genomic Testing ...

* Context.-Tests that are performed outside of the ordering institution, send-out tests, represent an area of risk to patients because of complexity associated with sending tests out. Risks related to ...

Laboratories use the same laboratory equipment they invested in for COVID testing to perform PGx testing. With COVID testing reimbursement dropping, many laboratorians are considering implementing PGx ...

Laboratory tests represent the single highest-volume medical intervention, with over 7 billion tests performed every year in the U.S. Although results from diagnostic testing are estimated to ...

Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget’s Disease of the Vulva The routine use of large next-generation sequencing (NGS) pan-cancer panels is required to identify ...

Does health information exchange actually have an effect on utilization of healthcare services? That's a question the University of Colorado Health Sciences Center will attempt to answer by analyzing ...

Simple restructuring of a computerized order form significantly reduced the number of laboratory tests suspected of being unnecessary or redundant. Pre—post intervention. Methods: A new version of the ...

Indianapolis-based Hc1.com, whose software helps health care organizations interpret data to personalize care and control costs, has reached a breakthrough deal with lab-testing giant Quest ...

Current Practices, Perceived Barriers, and Promising Implementation Strategies for Improving Quality of Smoking Cessation Support in Accredited Cancer Programs of the American College of Surgeons This ...

Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however its use has complicated the diagnosis of non-small-cell lung cancer ...